Research perspectives: The future of the management of metastatic triple-negative breast cancers
Type de matériel :
TexteLangue : français Détails de publication : 2022.
Ressources en ligne : Abrégé : Triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis. Until recently, this disease was solely treated with chemotherapy. However, it has been the subject of much research and therapeutic progress. The success of immunotherapy and antibody-drug conjugates (ADC) has finally opened up new possibilities for both advanced and early stages of the disease. In this review, we discuss the ongoing efforts to improve the effectiveness of immunotherapy through new approaches. We also review the numerous ADC in development and their targets. Finally, we examine the potential role of targeted therapies, such as PI3K/AKT/mTOR inhibitors and hormone therapy approaches.
Nous n'avons pas d'exemplaire de ce document
70
Triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis. Until recently, this disease was solely treated with chemotherapy. However, it has been the subject of much research and therapeutic progress. The success of immunotherapy and antibody-drug conjugates (ADC) has finally opened up new possibilities for both advanced and early stages of the disease. In this review, we discuss the ongoing efforts to improve the effectiveness of immunotherapy through new approaches. We also review the numerous ADC in development and their targets. Finally, we examine the potential role of targeted therapies, such as PI3K/AKT/mTOR inhibitors and hormone therapy approaches.
Réseaux sociaux